None listed
Conditions
Interventions
None listed
Sponsors
The Catholic University of Korea, Seoul St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient: 1. Individuals aged 70 and above. 2. Those who can read and understand documents written in Korean. 3. Patients who have been diagnosed with multiple myeloma by a healthcare professional and fall into one of the following treatment stages: newly diagnosed and scheduled for treatment, undergoing 1st or 2nd line treatment, or in a relevant condition after treatment. Recurrent/resistant patients requiring additional treatment for multiple myeloma after the 3rd line of treatment. 4.Must sign an Informed Consent Form (ICF) allowing data collection and confirmation of evidence based on local requirements. Caregiver: 1. Individuals aged 18 and above. 2. Those who can read and understand documents written in Korean. 3. Individuals providing care for a multiple myeloma patient and well-informed about the treatment options for the condition. The survey includes questions about whether the caregiver currently lives with the patient or is the primary family member providing financial support to the patient. 4. Must sign an Informed Consent Form (ICF) allowing data collection and confirmation of evidence based on local requirements. Physician: 1. Those who can read and understand documents written in Korean. 2. Individuals with more than 3 years of experience in treating multiple myeloma patients. 3. Those who diagnose/monitor more than 50 multiple myeloma patients annually. 4. Individuals with over 3 years of experience discussing multiple myeloma treatment and management with other healthcare professionals such as hematologists/oncologists, 'multiple myeloma specialist' (key opinion leaders)/conference speakers. 5. Must agree to participate in the study before the online survey.
Exclusion criteria
Exclusion criteria: N/A
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative Importance of Attributes: What is the perceived relative importance of various treatment attributes according to Korean multiple myeloma stakeholders (patients, caregivers, physicians)? | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life: How does the treatment scenario impact the quality of life? | — |
Countries
Korea, Republic of
Contacts
Public ContactJun SeungMin
The Catholic University of Korea, Seoul St. Mary's Hospital
Outcome results
None listed